CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer-Reference-Cited by-同舟云学术

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer

Published:2016-06-13 Issue:7 Volume:126 Page:2610-2620
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Weiskopf Kipp,Jahchan Nadine S.,Schnorr Peter J.,Cristea Sandra,Ring Aaron M.,Maute Roy L.,Volkmer Anne K.,Volkmer Jens-Peter,Liu Jie,Lim Jing Shan,Yang Dian,Seitz Garrett,Nguyen Thuyen,Wu Di,Jude Kevin,Guerston Heather,Barkal Amira,Trapani Francesca,George Julie,Poirier John T.,Gardner Eric E.,Miles Linde A.,de Stanchina Elisa,Lofgren Shane M.,Vogel Hannes,Winslow Monte M.,Dive Caroline,Thomas Roman K.,Rudin Charles M.,van de Rijn Matt,Majeti Ravindra,Garcia K. Christopher,Weissman Irving L.,Sage Julien

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference54 articles.

1. Characterization of the cell of origin for small cell lung cancer

2. Cell of Origin of Small Cell Lung Cancer: Inactivation of Trp53 and Rb1 in Distinct Cell Types of Adult Mouse Lung

3. Small-cell lung cancer

4. Small cell lung cancer: Where do we go from here?

5. The blockade of immune checkpoints in cancer immunotherapy

Cited by 343 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer Therapy-induced Dermatotoxicity as a Window to Understanding Skin Immunity;Hematology/Oncology Clinics of North America;2024-10

2. In situ reprogramming of tumor-associated macrophages enhances cancer immunotherapy;Nano Today;2024-10

3. Paradoxical cell targeting of calreticulin-empowered, protein-only nanoparticles;European Journal of Pharmaceutics and Biopharmaceutics;2024-09

4. The human CD47 checkpoint is targeted by an immunosuppressive Aedes aegypti salivary factor to enhance arboviral skin infectivity;Science Immunology;2024-08-09

5. Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities;Experimental Hematology & Oncology;2024-08-05